/CAI
CAI Stock - Caris Life Sciences, Inc.
Healthcare|BiotechnologyNASDAQ
$27.94+0.29%
+$0.08 (+0.29%) • Dec 19
58
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.42
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).50
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+0.2%upside
Target: $28.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CAI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$27.66 – $28.22
TARGET (TP)$28.00
STOP LOSS$25.70
RISK/REWARD1:0.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-1.17
52W High$42.50
52W Low$22.86
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $412.26M | $306.13M | $258.49M | $294.01M | $416.54M |
| Gross Profit | $178.78M | $89.31M | $80.02M | $184.16M | $200.51M |
| Gross Margin | 43.4% | 29.2% | 31.0% | 62.6% | 48.1% |
| Operating Income | $-257,122,000 | $-319,551,000 | $-315,756,000 | $139.09M | $130.28M |
| Net Income | $-281,890,000 | $-341,415,000 | $-320,827,000 | $27.73M | $31.01M |
| Net Margin | -68.4% | -111.5% | -124.1% | 9.4% | 7.4% |
| EPS | $-2.70 | $-1.82 | $-1.57 | $1.55 | $1.72 |
Company Overview
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
88%
Hold / Neutral
1
13%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
7 Bullish1 Neutral/Bearish
Price Targets
$32
Average Target
↑ 15.7% Upside
Now
$28
Low
$32
Average
$38
High
Based on 9 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 2nd 2025 | Canaccord Genuity | Initiation | Hold | $28 |
| July 14th 2025 | BofA Securities | Initiation | Buy | $31 |
| July 14th 2025 | JP Morgan | Initiation | Overweight | $31 |
| July 14th 2025 | Guggenheim | Initiation | Buy | $32 |
| July 14th 2025 | Evercore ISI | Initiation | Outperform | $33 |
| July 14th 2025 | TD Cowen | Initiation | Buy | $32 |
| July 14th 2025 | BTIG Research | Initiation | Buy | $38 |
| July 14th 2025 | Citigroup | Initiation | Buy | $34 |
| July 14th 2025 | Wolfe Research | Initiation | Outperform | $32 |
Earnings History & Surprises
CAIBeat Rate
50%
Last 2 quarters
Avg Surprise
+21.4%
EPS vs Estimate
Beats / Misses
1/1
Last 12 quarters
Latest EPS
$0.08
Q4 2025
EPS Surprise History
Q3 25
-157.1%
$-0.54vs$-0.21
Q4 25
+200.0%
$0.08vs$-0.08
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 5, 2025 | $-0.08 | $0.08 | +200.0% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-0.21 | $-0.54 | -157.1% | ✗ MISS |
Latest News
Caris Life Sciences' Caris Discovery Signs License Agreement With Genentech To Identify, Validate Oncology Targets In Solid Tumor Tissue
📈 PositiveBenzinga•Dec 16, 2025, 01:37 PM
Canaccord Genuity Initiates Coverage On Caris Life Sciences with Hold Rating, Announces Price Target of $28
➖ NeutralBenzinga•Dec 2, 2025, 12:31 PM•Also:
CAI stock has given up its prior gain. CAI stock has given up its prior gain.
📉 NegativeBenzinga•Nov 6, 2025, 02:49 PM
CAI stock has given up its prior gain. Caris Life Sciences shares were trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.
➖ NeutralBenzinga•Nov 6, 2025, 11:24 AM
CAI stock has given up its prior gain. Caris Life Sciences shares were trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.
➖ NeutralBenzinga•Nov 5, 2025, 11:20 PM
Caris Life Sciences shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.
📈 PositiveBenzinga•Nov 5, 2025, 10:13 PM
Caris Life Sciences Raises FY2025 Sales Guidance from $675.000M-$685.000M to $720.000M-$730.000M vs $680.242M Est
📈 PositiveBenzinga•Nov 5, 2025, 09:37 PM
Caris Life Sciences Q3 EPS $0.08 Beats $(0.12) Estimate, Sales $216.833M Beat $200.587M Estimate
📈 PositiveBenzinga•Nov 5, 2025, 09:36 PM
Caris Life Sciences Identifies Tet2 Clonal Hematopoiesis As Biomarker For Enhanced Response To Immune Checkpoint Inhibitor Therapy In Patients With Solid Tumors
📈 PositiveBenzinga•Oct 29, 2025, 12:36 PM
Caris Life Sciences trades higher on market debut
📈 PositiveSeeking Alpha•Jun 18, 2025, 05:18 PM
Frequently Asked Questions about CAI
What is CAI's current stock price?
Caris Life Sciences, Inc. (CAI) is currently trading at $27.94 per share. The stock has moved +0.29% today.
What is the analyst price target for CAI?
The average analyst price target for CAI is $28.00, based on 1 analyst.
What sector is Caris Life Sciences, Inc. in?
Caris Life Sciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CAI's market cap?
Caris Life Sciences, Inc. has a market capitalization of $7.88 billion, making it a mid-cap company.
Does CAI pay dividends?
No, Caris Life Sciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABVX
Abivax S.A.
$114.94
Mkt Cap: $7.5B
CORT
Corcept Therapeutics Incorporated
$83.76
Mkt Cap: $8.8B
CYTK
Cytokinetics, Incorporated
$62.72
Mkt Cap: $7.5B
HALO
Halozyme Therapeutics, Inc.
$67.35
Mkt Cap: $7.9B
JAZZ
Jazz Pharmaceuticals plc
$166.99
Mkt Cap: $10.1B
MDGL
Madrigal Pharmaceuticals, Inc.
$591.02
Mkt Cap: $13.1B
MRNA
Moderna, Inc.
$33.80
Mkt Cap: $13.2B
MRUS
Merus N.V.
$97.01
Mkt Cap: $7.4B
RNA
Avidity Biosciences, Inc.
$72.34
Mkt Cap: $9.5B
RYTM
Rhythm Pharmaceuticals, Inc.
$112.14
Mkt Cap: $7.5B
Explore stocks similar to CAI for comparison